Dyadic International (DYAI) to Release Quarterly Earnings on Wednesday

Dyadic International (NASDAQ:DYAI) is projected to post its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Dyadic International to post earnings of ($0.03) per share and revenue of $1.0250 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:00 PM ET.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. On average, analysts expect Dyadic International to post $0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Dyadic International Trading Up 3.2%

NASDAQ:DYAI opened at $1.11 on Wednesday. The company has a market capitalization of $40.63 million, a P/E ratio of -4.85 and a beta of 1.12. The stock’s 50 day moving average price is $0.94 and its 200 day moving average price is $0.86. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International has a 52 week low of $0.65 and a 52 week high of $1.60.

Hedge Funds Weigh In On Dyadic International

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the third quarter valued at $190,000. Finally, Geode Capital Management LLC raised its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares in the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.